Preclinical dual-modality study pairs senolytic immune therapy with stem cell regeneration and examines translational implications for aging interventions.
Key Takeaways
- Collaboration reported more than a 70% lifespan increase in treated mice
- Intervention paired immune-based senescent cell clearance with personalized mesenchymal stem cell therapy
- Researchers from multiple institutions contributed and the companies said a full manuscript is available